Webinar March 2026 – Prof. van der Meel

On Wednesday, March 18, 2026, an online seminar on "Apolipoprotein nanoparticle platform technology for RNA delivery to immune cells" will be held at 3.30 p.m. (CET).

The speaker will be Prof. Dr. Roy van der Meel from Eindhoven University of Technology, the Netherlands.

Here you can register for the webinar.

Abstract

Nucleic acid therapeutics hold great promise for gene silencing, expression, or editing but require sophisticated nanotechnologies to achieve efficient delivery following systemic administration. Lipid nanoparticle (LNP) technology is currently the gold-standard delivery platform, enabling the clinical translation of the first siRNA drug and mRNA vaccines. However, approved LNP systems are largely optimized for vaccine applications via local administration or hepatic delivery following intravenous administration.

To enable therapeutic applications beyond the liver, we have recently developed a nanotechnology-based delivery platform derived from natural lipoproteins for targeted and intracellular RNA delivery to immune cells. By leveraging the inherent ability of the apolipoprotein nanoparticle (aNP) platform to engage immune cells, we achieve functional gene silencing or gene expression in specific immune cell subsets and their bone marrow progenitors, thereby creating new opportunities for immunotherapy development.